
Anumana Receives FDA 510k Approval for New AI Powered Heart Failure Diagnosis Technology
Anumana, Inc., a leading AI-driven health technology company, in collaboration with Mayo Clinic, has achieved FDA 510(k) clearance for ECG-AI LEF, a new artificial intelligence (AI)-powered medical device designed to detect low ejection fraction (LEF) in patients at risk of heart failure. LEF, often asymptomatic and underdiagnosed, is a significant indicator of heart failure. Ejection fraction measures the total amount of blood in the left ventricle is pushed out with each heartbeat. A normal heart’s ejection fraction is between 55 and 70 percent. An ejection fraction below 40% is often associated with heart failure.
Developed in partnership with Mayo Clinic, ECG-AI LEF is an innovative software-as-a-medical device (SaMD) designed to screen for LEF in adults at risk for heart failure using data from a routine 12-lead electrocardiogram (ECG). The algorithm was developed based on research from Mayo Clinic, utilizing data from over 100,000 ECG and echocardiogram pairs from unique patients and tested in more than 25 studies involving over 40,000 patients in the U.S. and internationally.
The clinical validation of ECG-AI LEF involved a retrospective study of 16,000 racially diverse patients, demonstrating an 84.5% sensitivity and 83.6% specificity. The algorithm achieved an AUROC of 0.932, indicating its ability to differentiate between LEF and ejection fraction (EF) >40% exceptionally well.
Additionally, the EAGLE study, a prospective clinical trial by Mayo Clinic involving 22,641 adults and 120 primary care teams from 45 clinics or hospitals, showed that ECG-AI LEF improved the diagnosis of LEF by 31% compared to standard care without increasing the overall rate of echocardiogram usage.
“Anumana’s ECG-AI LEF fills an important unmet need – the lack of an easily accessible point-of-care, noninvasive, and inexpensive tool to screen for a weak heart pump,” said Dr. Paul Friedman, Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Chair of Anumana’s Board of Advisors. “It allows identification of otherwise hidden disease, for which many effective, lifesaving treatments are available – once the presence of the disease is known.”
Anumana’s ECG-AI LEF is part of its broader pipeline of algorithms, including three additional FDA breakthrough device designation algorithms. The company has also been instrumental in securing reimbursement for ECG-AI, receiving approval for two Category III CPT® codes from the American Medical Association in 2022, facilitating the adoption of emerging technologies in clinical workflows.